NCT05696366View on ClinicalTrials.gov

Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Type 1 Diabetes
Interventions
DRUG

Sotagliflozin

Sotagliflozin is a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 (SGLT1/2) inhibitor.

DRUG

Volagidemab

Volagidemab is a human monoclonal antibody glucagon receptor antagonist (GRA).

Trial Locations (1)

92037

RECRUITING

UC San Diego Altman Clinical & Translational Research Institute, La Jolla

Sponsors
All Listed Sponsors
collaborator

Lexicon Pharmaceuticals

INDUSTRY

collaborator

Breakthrough T1D

OTHER

lead

University of California, San Diego

OTHER